Publications and communications of Ehx, Grégory

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell. doi:10.1016/j.ccell.2022.02.005

Ruiz, M. V., Apavaloaei, A., Zhao, Q., Hardy, M.-P., Lemieux, S., Perreault, C., & Ehx, G. (04 September 2021). BamQuery: A new proteogenomic tool to explore the immunopeptidome and validate tumor‐specific antigens. Paper presented at 6th European Congress of Immunology, Belgrade, Serbia.

Ruiz, M. V., Apavaloaei, A., Zhao, Q., Hardy, M.-P., Lemieux, S., Perreault, C., & Ehx, G. (August 2021). BamQuery: A new proteogenomic tool to explore the immunopeptidome and validate tumor‐specific antigens. European Journal of Immunology, 51 (S1), 60. doi:10.1002/eji.202170200

Ehx, G. (05 May 2021). Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Paper presented at 88th meeting of the French-Language Learned Society - Functional Genomic symposium, Sherbrooke, Canada.

Ehx, G. (30 April 2021). Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Paper presented at EORTC Leukemia Group Spring Meeting.

Ehx, G., Larouche, J.-D., Durette, C., Laverdure, J.-P., Hesnard, L., Vincent, K., Hardy, M.-P., Thériault, C., Rulleau, C., Lanoix, J., Bonneil, E., Feghaly, A., Apavaloaei, A., Noronha, N., Laumont, C. M., Delisle, J.-S., Vago, L., Hébert, J., Sauvageau, G., & Perreault, C. (13 April 2021). Atypical acute myeloid leukemia-specific transcripts generate shared and immunogenic MHC class-I-associated epitopes. Immunity, 54 (4), 737-752. doi:10.1016/j.immuni.2021.03.001

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Ehx, G., Ritacco, C., HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505

Ritacco, C., Ehx, G., GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0

Ritacco, C., Ehx, G., Canti, L., DUBOIS, S., Vandenhove, B., SERVAIS, S., Beguin, Y., & Baron, F. (01 March 2020). Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects. Biology of Blood and Marrow Transplantation, 26 (3), 168. doi:10.1016/j.bbmt.2019.12.028

Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020). MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of hematology & oncology, 13 (1), 173. doi:10.1186/s13045-020-01007-9

Larouche, J.-D., Trofimov, A., Hesnard, L., Ehx, G., Zhao, Q., Vincent, K., Durette, C., Gendron, P., Laverdure, J.-P., Bonneil, E., Coté, C., Lemieux, S., Thibault, P., & Perreault, C. (2020). Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues. Genome Medicine, 12 (1). doi:10.1186/s13073-020-00740-7

Noronha, N.* , Ehx, G.* , Meunier, M.-C., Laverdure, J.-P., Thériault, C., & Perreault, C. (2020). Major multilevel molecular divergence between THP-1 cells from different biorepositories. International Journal of Cancer, 147 (7), 2000-2006. doi:10.1002/ijc.32967

Ehx, G., Noronha, N., Vincent, K., Laverdure, J.-P., Lanoix, J., Durette, C., Lemieux, S., Thibault, P., & Perreault, C. (18 September 2019). The impact of hypomethylation on the immunopeptidome of acute myeloid leukemia. Paper presented at Canadian Cancer Immunotherapy Consortium Annual Meeting, Toronto, Canada.

Ehx, G. (31 May 2019). The tumor-specific antigens landscape in acute myeloid leukemia. Paper presented at 10th Antigen Processing and Presentation meeting of the European Molecular Biology Organization (EMBO), Paris, France.

Ehx, G., Vincent, K., Larouche, J.-D., Durette, C., Laverdure, J.-P., Lanoix, J., Bonneil, E., Hardy, M.-P., Coté, C., Noronha, N., Hesnard, L., Zhao, Q., Laumont, C., Lemieux, S., Thibault, P., & Perreault, C. (31 May 2019). The tumor-specific antigens landscape in acute myeloid leukemia. Poster session presented at 10th Antigen Processing and Presentation meeting of the European Molecular Biology Organization (EMBO), Paris, France.

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Ehx, G., & Perreault, C. (2019). Discovery and characterization of actionable tumor antigens. Genome Medicine, 11 (1). doi:10.1186/s13073-019-0642-x

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Colonval, M., Iovino, M., Esser, N., Dehairs, J., Ehx, G., Baron, F., Piette, J., Swinnen, J., Paquot, N., & Legrand, S. (26 June 2018). Obesity induces metabolic and phenotypic variations in blood monocytes and NK cells. Poster session presented at Cell Symposia: Translational Immunometabolism.

Dupont, L., Ehx, G., Chantry, M., Monseur, C., Leduc, C., Janssen, L., Cataldo, D., Thiry, M., Jérôme, C., Thomassin, J.-M., Nusgens, B., Dubail, J., Baron, F., & Colige, A. (2018). Spontaneous atopic dermatitis due to immune dysregulation in mice lacking Adamts2 and 14. Matrix Biology, 70, 140-157. doi:10.1016/j.matbio.2018.04.002

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, F., & BARON, F. (24 May 2017). Th17 cells impact on xenogeneic graft-versus-host disease. Poster session presented at 2017 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

Ehx, G. (2017). Prevention of xenogeneic GVHD in NSG mice infused with human PBMC: assessment of Treg promoting therapies. Unpublished doctoral thesis, ULiège - Université de Liège.
Jury: Baron, F. (Promotor), Piette, J. (Promotor), Sadzot, C., Beguin, Y., Geenen, V., Cohen, J., Coulie, P., & Moutschen, M.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., Beguin, Y., & Baron, F. (27 March 2017). Xenogeneic graft-versus-host disease : Impact of Th17 cells. Poster session presented at 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, Marseille, France.

Ehx, G., Hannon, M., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (March 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Biology of Blood and Marrow Transplantation, 23 (3), 365–S366. doi:10.1016/j.bbmt.2016.12.314

Ehx, G., HANNON, M., Dubois, S., Daulne, C., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (10 February 2017). Immunomodulatory effects of rapamycin in xenogeneic Graft versus Host Disease. Journal of Clinical Immunology, 37 (2), 197-266. doi:10.1007/s10875-017-0372-z

Ehx, G., SOMJA, J., Fransolet, G., Delens, L., Muller, J., BEGUIN, Y., Humblet-Baron, S., Hannon, M., & BARON, F. (10 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice. Poster session presented at 32nd General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (February 2017). Impact of Th17 population on xenogeneic graft-versus-host disease. Poster session presented at 32nd General Annual Meeting of the Belgian Hematology Society, La Hulpe, Belgium.

Ehx, G., SOMJA, J., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Hannon, M., Humblet-Baron, S., & BARON, F. (01 February 2017). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice. Paper presented at GIGA-Day 2017: New insights into the hallmark of cancer, Liège, Belgium.

Ehx, G., & Baron, F. (2017). Immune recovery predicts survival after T-cell depleted allogeneic hematopoietic cell transplantation. Leukemia and Lymphoma, 58, 1774-1776. doi:10.1080/10428194.2017.1283688

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (08 December 2016). Xenogeneic graft-versus-host disease: Impact of Th17 cells. Poster session presented at Journée des chercheurs Télévie 2017, Bruxelles, Belgium.

Fransolet, G., Belle, L., SOMJA, J., DELVENNE, P., Hannon, M., Drion, P., BINSFELD, M., BEGUIN, Y., Ehx, G., & Baron, F. (08 December 2016). Limited impact of imatinib in a murine model of sclerodermatous chronic graft-versus-host disease (scl-cGVHD). Paper presented at Séminaire des chercheurs Télévie 2017, Bruxelles, Belgium.

Delens, L., SERVAIS, S., Ehx, G., Vrancken, L., Fransolet, G., GREGOIRE, C., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & BARON, F. (18 November 2016). Impact des cellules Th17 sur la GVH xénogénique. Paper presented at 16ème édition du congrès de la SFGM-TC, Société Francophone de Greffe de Moelle et de Thérapie Cellulaire, Liège, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (18 November 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Paper presented at Congrès Commun de la SFGM-TC et de la SFBCT, Liège, Belgium.

Belle, L., Fransolet, G., SOMJA, J., BINSFELD, M., DELVENNE, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G., & Baron, F. (17 November 2016). Limited impact of imatinib in a murine model of sclerodermic chronic graft-versus-host disease. Poster session presented at 16ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC) en commun avec la SFBCT, Liège, Belgium.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (14 October 2016). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Poster session presented at Regulatory T cell mini-symposium, Leuven, Belgium.

Ehx, G., Somja, J., Fransolet, G., Delens, L., Muller, J., Beguin, Y., Humblet-Baron, S., & Baron, F. (14 October 2016). Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice. Poster session presented at Regulatory T cells mini-symposium, Leuven, Belgium.

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2

Delens, L., BEGUIN, Y., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., SERVAIS, S., & BARON, F. (27 May 2016). Th17 cell population seems to aggravate xenogeneic graft-versus-host disease. Poster session presented at 2016 Immunology day FNRS-Immunology Doctoral School, Gosselies, Belgium.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (March 2016). Azacytidine Enhances Regulatory T-Cells In Vivo and Prevents Experimental Xenogeneic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 22 (3), 393. doi:10.1016/j.bbmt.2015.11.917

Delens, L., SERVAIS, S., Vrancken, L., Ehx, G., Fransolet, G., Hannon, M., DUBOIS, S., Daulne, C., BEGUIN, Y., & Baron, F. (29 January 2016). Salt but not glucocorticoïds enhances Th17 differentiation from naïve T cells in vitro. Poster session presented at 31st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G., Hannon, M., Humblet-Baron, S., DUBOIS, S., Daulne, C., Drion, P., BEGUIN, Y., & BARON, F. (29 January 2016). Immunomodulatory effects of rapamycin in Graft versus Host Disease. Poster session presented at 31st General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Delens, L., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., DELVENNE, P., BEGUIN, Y., Conteduca, G., & Baron, F. (29 January 2016). Azacytidine and Decitabine prevent experimental sclerodermic chronic graft-versus-host disease. Poster session presented at 31st general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Grégoire, C., Beguin, Y., Hannon, M., DUBOIS, S., BAUDOUX, E., BRIQUET, A., LECHANTEUR, C., Ehx, G., & Baron, F. (29 January 2016). Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice. Poster session presented at 31th General Meeting of the Belgian Hematological Society.

Göktuna, S., Shostak, K., Chau, T.-L., Heukamp, L., Hennuy, B., Duong, H. Q., LADANG, A., Close, P., Klevernic, I., Olivier, F., Florin, A., Ehx, G., Baron, F., Vandereyken, M., Rahmouni, S., Vereecke, L., van Loo, G., Büttner, R., Greten, F., & Chariot, A. (2016). The Prosurvival IKK-Related Kinase IKK« Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. Cancer Research, 76, 2587-99. doi:10.1158/0008-5472.CAN-15-1473

Delens, L., Servais, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Daulne, C., Vrancken, L., Beguin, Y., & Baron, F. (03 December 2015). Revisiting Th17 cell subsets in the setting of allogeneic stem cell transplantation and (cortico-refractory) graft-versus-host disease. Poster session presented at Journée Télévie 2016, Gembloux, Belgium.

Ehx, G., & BARON, F. (19 November 2015). Unraveling immune recovery after allogeneic hematopoietic stem cell transplantation: the contribution of flow cytometry. Paper presented at Advances in Immunomonitoring by Flow Cytometry, Antwerpen, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale. Paper presented at 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

Ehx, G., Fransolet, G., de Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., BEGUIN, Y., Humblet-Baron, S., & BARON, F. (13 November 2015). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Paper presented at EORTC Leukemia Group-GIMEMA meeting, Rome, Italy.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

Delens, L., SERVAIS, S., Hannon, M., Ehx, G., Fransolet, G., DUBOIS, S., Beguin, Y., & Baron, F. (30 January 2015). Effects of Tocilizumab on Th17 cell differentiation in a humanized mouse model of xenogeneic graft-versus-host disease. Poster session presented at 30st General Annual Meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G. (30 January 2015). Azacytidine augments regulatory T cells and prevents experimental xenogeneic graft-versus-host disease. Paper presented at 30th General Annual Meeting of the Belgian Hematological Society, Bruxelles, Belgium.

Fransolet, G., Ehx, G., SOMJA, J., Belle, L., Drion, P., Humblet-Baron, S., Beguin, Y., & Baron, F. (30 January 2015). Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease. Poster session presented at 30th general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G.* , Hannon, M.* , BEGUIN, Y., Humblet-Baron, S.* , & BARON, F.*. (2015). Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget, 6, 43255-43266. doi:10.18632/oncotarget.6486

Ehx, G.* , Gerin, S.* , Mathy, G., Franck, F., Oliveira, H. C., Vercesi, A. E., & Sluse, F. (21 July 2014). Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels. Lipids in Health and Disease, 13, 116. doi:10.1186/1476-511X-13-116

Ehx, G. (12 June 2014). Use of PerFix EXPOSE for STAT5 phosphorylation level monitoring in regulatory T cells. Paper presented at Flow Cytometry Meeting.

Ehx, G. (11 April 2014). Xenogeneic GVHD in NSG mice: focus on rapamycin. Paper presented at Mini symposium on GVHD, Louvain-la-Neuve, Belgium.

Ehx, G. (31 January 2014). Immunomodulatory effects of Rapamycin in xenogeneic GVHD. Poster session presented at BHS General Annual Meeting 2014.

Ehx, G., HANNON, M., DUBOIS, S., HALLEUX, A., Belle, L., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (27 January 2014). Immunomodulatory effects of Rapamycin in xenogeneic GVHD. Poster session presented at GIGA Day 2014, Liège, Belgium.

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

Belle, L., Ehx, G., SOMJA, J., Binsfeld, M., HANNON, M., CAERS, J., Fransolet, G., BEGUIN, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Poster session presented at 55th Annual Meeting of the American Society of Hematology.

Belle, L., Ehx, G., SOMJA, J., BINSFELD, M., Hannon, M., Caers, J., Fransolet, G., Beguin, Y., Humblet-Baron, S., & Baron, F. (December 2013). Combination Of Regulatory T Cells and Rapamycin As Treatment For Experimental Chronic Graft-Versus-Host Disease. Blood, 122 (21), 4474.

Ehx, G. (2011). Etude protéomique de l'incidence d'une hypertriglycéridémie sur le métabolisme hépatique de la souris. Unpublished master thesis, ULiège - Université de Liège.
Jury: Franck, F. (Promotor), & Sluse, F. (Promotor).